Novartis’ Zolgensma woes, BIO’s China plan, GLP-1s’ new safety warning, FDA’s stacked November

0:00-23:50

Novartis confirms that nine patients treated with its spinal muscular atrophy gene therapy Zolgensma have developed tumors; the FDA orders GLP-1 drugmakers to add a warning to their labels about the risk of a rare eye condition that can lead to vision loss; and the agency is set to decide on no fewer than 11 therapies this month, including closely watched applications from Summit Therapeutics, Vertex and Capricor Therapeutics.

Publisher

BioSpace

Published

November 11, 2026

Duration

24 min

Format

Podcast

Category

Issues · Science

Source

RSS feed

B

BioSpace

@biospace

#novartiszolgensmawoes #bioschinaplan #fdasstackednovember #lifesciences

The Nile